(ABCL) Abcellera Biologics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.270m USD | Total Return: 160% in 12m

Antibodies, Discovery Platform, Monoclonal Antibodies, Biologics
Total Rating 46
Safety 57
Buy Signal 0.30
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.27B
Avg Turnover: 46.0M
Risk 3d forecast
Volatility80.7%
VaR 5th Pctl13.1%
VaR vs Median-1.83%
Reward TTM
Sharpe Ratio1.55
Rel. Str. IBD93
Rel. Str. Peer Group80.8
Character TTM
Beta2.209
Beta Downside2.253
Hurst Exponent0.517
Drawdowns 3y
Max DD75.72%
CAGR/Max DD-0.11
CAGR/Mean DD-0.18
EPS (Earnings per Share) EPS (Earnings per Share) of ABCL over the last years for every Quarter: "2021-03": 0.37, "2021-06": -0.01, "2021-09": -0.08, "2021-12": 0.19, "2022-03": 0.54, "2022-06": -0.02, "2022-09": 0.08, "2022-12": -0.1, "2023-03": -0.14, "2023-06": -0.11, "2023-09": -0.1, "2023-12": -0.17, "2024-03": -0.14, "2024-06": -0.13, "2024-09": -0.17, "2024-12": -0.12, "2025-03": -0.15, "2025-06": -0.12, "2025-09": -0.19, "2025-12": -0.03, "2026-03": -0.1424,
Last SUE: -0.32
Qual. Beats: 0
Revenue Revenue of ABCL over the last years for every Quarter: 2021-03: 202.741, 2021-06: 27.643, 2021-09: 5.508, 2021-12: 139.331, 2022-03: 316.581, 2022-06: 45.917, 2022-09: 101.383, 2022-12: 21.545, 2023-03: 12.192, 2023-06: 10.056, 2023-09: 6.599, 2023-12: 9.179, 2024-03: 9.954, 2024-06: 7.323, 2024-09: 6.507, 2024-12: 5.05, 2025-03: 4.235, 2025-06: 17.084, 2025-09: 8.955, 2025-12: 44.853, 2026-03: 8.315,
Rev. CAGR: -7.04%
Rev. Trend: -12.5%
Last SUE: 0.17
Qual. Beats: 0

Warnings

Interest Coverage Ratio -12.8 is critical

Extended 1w Choppy

Tailwinds

Leader, Confidence

Description: ABCL Abcellera Biologics

AbCellera Biologics Inc. is a Canada-based biotechnology firm focused on the discovery and development of antibody-based therapeutics. The company’s internal pipeline features ABCL635, currently in Phase 2 trials for vasomotor symptoms, and ABCL575, a monoclonal antibody in Phase 1 trials for autoimmune conditions. Its business model relies heavily on strategic partnerships, maintaining active research collaborations with major pharmaceutical entities including Eli Lilly, AbbVie, and Biogen.

The biotechnology sector is characterized by high research and development costs and long regulatory timelines, often requiring firms to leverage platform technologies to accelerate drug discovery. AbCellera utilizes a partnership-driven approach to offset these risks, earning revenue through licensing agreements and milestone payments rather than immediate product sales. For a more comprehensive look at these financial drivers, consider reviewing the detailed metrics available on ValueRay.

Headlines to Watch Out For
  • Advancement of lead internal programs ABCL635 and ABCL575 through clinical trial milestones
  • Expansion of partnership pipeline with Eli Lilly and AbbVie drives milestone payments
  • Strategic shift toward internal drug development increases research and development capital expenditure
  • High interest rates impact valuation of pre-revenue biotechnology firms and financing costs
  • Success of AI-driven antibody discovery platform in securing high-value licensing agreements
Piotroski VR-10 (Strict) 1.0
Net Income: -144.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.14 > 0.02 and ΔFCF/TA -3.86 > 1.0
NWC/Revenue: 779.4% < 20% (prev 2.98k%; Δ -2.20k% < -1%)
CFO/TA -0.12 > 3% & CFO -153.3m > Net Income -144.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 14.05 > 1.5 & < 3
Outstanding Shares: last quarter (303.1m) vs 12m ago 1.81% < -2%
Gross Margin: 63.61% > 18% (prev -4.74%; Δ 6.84k% > 0.5%)
Asset Turnover: 5.97% > 50% (prev 1.72%; Δ 4.26% > 0%)
Interest Coverage Ratio: -12.77 > 6 (EBITDA TTM -174.7m / Interest Expense TTM 16.1m)
Altman Z'' 5.91
A: 0.47 (Total Current Assets 664.6m - Total Current Liabilities 47.3m) / Total Assets 1.31b
B: -0.06 (Retained Earnings -72.6m / Total Assets 1.31b)
C: -0.16 (EBIT TTM -205.5m / Avg Total Assets 1.33b)
D: 3.84 (Book Value of Equity 741.5m / Total Liabilities 192.9m)
Altman-Z'' = 5.91 = AAA
Beneish M -1.90
DSRI: 0.27 (Receivables 115.7m/126.6m, Revenue 79.2m/23.1m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.97 (AQ_t 0.17 / AQ_t-1 0.17)
SGI: 3.43 (Revenue 79.2m / 23.1m)
TATA: 0.01 (NI -144.0m - CFO -153.3m) / TA 1.31b)
Beneish M = -1.90 (Cap -4..+1) = B
What is the price of ABCL shares?

As of May 24, 2026, the stock is trading at USD 5.20 with a total of 6,433,629 shares traded.
Over the past week, the price has changed by +27.14%, over one month by +27.45%, over three months by +71.62% and over the past year by +160.00%.

Is ABCL a buy, sell or hold?

Abcellera Biologics has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy ABCL.

  • StrongBuy: 6
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ABCL price?
Analysts Target Price 10.1 95%
Abcellera Biologics (ABCL) - Fundamental Data Overview as of 20 May 2026
P/E Forward = 27.5482
P/S = 16.0383
P/B = 1.3542
Revenue TTM = 79.2m USD
EBIT TTM = -205.5m USD
EBITDA TTM = -174.7m USD
Long Term Debt = 134.3m USD (estimated: total debt 140.2m - short term 5.87m)
Short Term Debt = 5.87m USD (from shortTermDebt, last quarter)
Debt = 140.2m USD (from shortLongTermDebtTotal, last quarter) (leases 143.2m already included)
Net Debt = -364.6m USD (calculated: Debt 140.2m - CCE 504.7m)
Enterprise Value = 905.8m USD (1.27b + Debt 140.2m - CCE 504.7m)
Interest Coverage Ratio = -12.77 (Ebit TTM -205.5m / Interest Expense TTM 16.1m)
EV/FCF = -4.79x (Enterprise Value 905.8m / FCF TTM -189.2m)
FCF Yield = -20.89% (FCF TTM -189.2m / Enterprise Value 905.8m)
 FCF Margin = -238.9% (FCF TTM -189.2m / Revenue TTM 79.2m)
 Net Margin = -181.7% (Net Income TTM -144.0m / Revenue TTM 79.2m)
Gross Margin = 63.61% ((Revenue TTM 79.2m - Cost of Revenue TTM 28.8m) / Revenue TTM)
Gross Margin QoQ = -4.09% (prev 82.34%)
Tobins Q-Ratio = 0.69 (Enterprise Value 905.8m / Total Assets 1.31b)
Interest Expense / Debt = 11.49% (Interest Expense 16.1m / Debt 140.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -162.4m (EBIT -205.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.05 (Total Current Assets 664.6m / Total Current Liabilities 47.3m)
Debt / Equity = 0.15 (Debt 140.2m / totalStockholderEquity, last quarter 938.1m)
 Debt / EBITDA = 2.09 (negative EBITDA) (Net Debt -364.6m / EBITDA -174.7m)
 Debt / FCF = 1.93 (negative FCF - burning cash) (Net Debt -364.6m / FCF TTM -189.2m)
 Total Stockholder Equity = 1.01b (last 4 quarters mean from totalStockholderEquity)
RoA = -10.86% (Net Income -144.0m / Total Assets 1.31b)
RoE = -13.26% (Net Income TTM -144.0m / Total Stockholder Equity 1.09b)
RoCE = -16.85% (EBIT -205.5m / Capital Employed (Equity 1.09b + L.T.Debt 134.3m))
 RoIC = -13.74% (negative operating profit) (NOPAT -162.4m / Invested Capital 1.18b)
 WACC = 13.29% (E(1.27b)/V(1.41b) * Re(13.75%) + D(140.2m)/V(1.41b) * Rd(11.49%) * (1-Tc(0.21)))
Discount Rate = 13.75% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 1.83%
 [DCF] Fair Price = unknown (Cash Flow -189.2m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.32 | # QB: 0
Revenue Correlation: -12.53 | Revenue CAGR: -7.04% | SUE: 0.17 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.17 | Chg30d=+15.00% | Revisions=+33% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.18 | Chg30d=+13.80% | Revisions=+33% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.66 | Chg30d=+7.00% | Revisions=+43% | GrowthEPS=-34.3% | GrowthRev=-58.6%
EPS next Year (2027-12-31): EPS=-0.72 | Chg30d=+8.08% | Revisions=+33% | GrowthEPS=-9.4% | GrowthRev=+10.2%
[Analyst] Revisions Ratio: +43%